Abbott Laboratories (ABT) — closed signal from January 1, 2026
Partial Published before the outcome was known, scored automatically when the window closed on April 1, 2026.
Predicted vs. what happened
What happened
Reached 27% of the predicted growth at its peak, without hitting the target.
The thesis — published January 1, 2026
Abbott just got regulatory approval for a medical device, which creates a clear short-term sales story and analysts expect multi-year earnings and sales growth. However, some research notes are lukewarm, so the market may have already priced in the good news. This makes it a steady, lower-volatility opportunity best bought on pullbacks rather than chased higher.
Primary drivers
- New approved device can bring weeks of customer and sales attention
- Healthcare focus tends to steady returns in the next few months
- Multiple product lines lower the risk from any one failure
- How well Abbott rolls out the product will drive near-term results
How it played out
ABT: thesis missed after a 3.3% peak
Lyra published ABT at 125.29 on 2026-01-01 with 12% expected growth and a 140.32 target. The thesis pointed to regulatory approval for a medical device, a short-term sales story, steady healthcare demand, multiple product lines, and execution of the rollout. It also noted that some research notes were lukewarm.
Inside the window, ABT rose to 129.46 on 2026-01-06, a 3.3% peak gain. It never reached 140.32. By 2026-04-01, it ended at 102.38. The published direction only partly showed up early, then failed. The thesis missed.
What happened during the window
On 2026-01-22, Investor's Business Daily reported Abbott's fourth-quarter 2025 results, with sales of 11.46 billion and a full-year 2026 adjusted earnings forecast of 5.55 to 5.80 per share. On 2026-01-28, Barron's reported that CEO Robert Ford bought 18,800 shares for about 2 million after the earnings drop.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.